secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-05-28T21:06:28+00:00
Accession:  0001193125-26-245484
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director
--------------------------------------------------------------------------------

- Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.
- Dr. Roberts receives $680k base salary, 60% target bonus, options for 476,190 shares, and 134,530 RSUs.
- Outgoing CEO David Chang, M.D., Ph.D. will remain on the Board as a non-employee director after June 30, 2026.
- Dr. Chang eligible for severance benefits under Allogene's Change in Control and Severance Benefit Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/d65280d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-245484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer